What question did this study set out to answer?

The aim is to develop selective COX inhibitors using rationally designed indole-oxadiazole derivatives.

Rational design and biological evaluation of naturally inspired indole-oxadiazole derivatives as potent COX inhibitors

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates potent COX inhibition in vitro, suggesting a pathway for drug design.

The aim is to develop selective COX inhibitors using rationally designed indole-oxadiazole derivatives.
Synthesized novel indole-oxadiazole derivatives with specific substitutions.
Evaluated in vitro COX-1 and COX-2 inhibition.
Conducted molecular docking and dynamics simulations to assess binding interactions.
IO-2 achieved IC50 of 0.198 µM for COX-1 and 0.158 µM for COX-2, demonstrating balanced activity.
IO-13 showed strong COX-1 inhibition with an IC50 of 0.175 µM.
Celecoxib, a reference, had an IC50 of 0.119 µM for COX-2, supporting the efficacy of new compounds.

Kuzu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates potent COX inhibition in vitro, suggesting a pathway for drug design.

The aim is to develop selective COX inhibitors using rationally designed indole-oxadiazole derivatives.
Synthesized novel indole-oxadiazole derivatives with specific substitutions.
Evaluated in vitro COX-1 and COX-2 inhibition.
Conducted molecular docking and dynamics simulations to assess binding interactions.
IO-2 achieved IC50 of 0.198 µM for COX-1 and 0.158 µM for COX-2, demonstrating balanced activity.
IO-13 showed strong COX-1 inhibition with an IC50 of 0.175 µM.
Celecoxib, a reference, had an IC50 of 0.119 µM for COX-2, supporting the efficacy of new compounds.

Kuzu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark